Lv2
128 积分 2023-04-21 加入
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2天前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2天前
已完结
High mitochondrial DNA levels accelerate lung adenocarcinoma progression
2天前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
3天前
已完结
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy
4天前
已完结
Urolithiasis in Patients Suffering from Malignant Hematologic Diseases
11天前
已完结
HRS-4642: The next piece of the puzzle to keep KRAS in check
29天前
已完结
KRAS takes the road to destruction
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1个月前
已完结
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
